| # | Title | Journal | Year | Citations |
|---|
| 1 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 | Neuro-Oncology | 2013 | 5,799 |
| 2 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary | Neuro-Oncology | 2021 | 4,534 |
| 3 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016 | Neuro-Oncology | 2019 | 1,735 |
| 4 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 | Neuro-Oncology | 2015 | 1,727 |
| 5 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015 | Neuro-Oncology | 2018 | 1,624 |
| 6 | The epidemiology of glioma in adults: a "state of the science" review | Neuro-Oncology | 2014 | 1,586 |
| 7 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009 | Neuro-Oncology | 2012 | 1,411 |
| 8 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011 | Neuro-Oncology | 2014 | 1,253 |
| 9 | The role of pericytes in blood-vessel formation and maintenance | Neuro-Oncology | 2005 | 1,252 |
| 10 | CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 | Neuro-Oncology | 2017 | 1,236 |
| 11 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017 | Neuro-Oncology | 2020 | 1,175 |
| 12 | A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma | Neuro-Oncology | 2003 | 1,071 |
| 13 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013 | Neuro-Oncology | 2016 | 995 |
| 14 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018 | Neuro-Oncology | 2021 | 804 |
| 15 | Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial | Neuro-Oncology | 2013 | 746 |
| 16 | Epidemiology of primary brain tumors: Current concepts and review of the literature | Neuro-Oncology | 2002 | 653 |
| 17 | GlioVis data portal for visualization and analysis of brain tumor expression datasets | Neuro-Oncology | 2017 | 622 |
| 18 | The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis | Neuro-Oncology | 2005 | 610 |
| 19 | Standards of care for treatment of recurrent glioblastoma—are we there yet? | Neuro-Oncology | 2013 | 592 |
| 20 | Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas | Neuro-Oncology | 2016 | 566 |
| 21 | Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis | Neuro-Oncology | 2005 | 550 |
| 22 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions | Neuro-Oncology | 2020 | 543 |
| 23 | Glioma cancer stem cells induce immunosuppressive macrophages/microglia | Neuro-Oncology | 2010 | 530 |
| 24 | The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1 | Neuro-Oncology | 2006 | 516 |
| 25 | IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas | Neuro-Oncology | 2009 | 504 |
| 26 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Neuro-Oncology | 2015 | 485 |
| 27 | Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study | Neuro-Oncology | 2017 | 483 |
| 28 | Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice | Neuro-Oncology | 2010 | 466 |
| 29 | PD-L1 expression and prognostic impact in glioblastoma | Neuro-Oncology | 2016 | 463 |
| 30 | Primary and secondary glioblastomas: From concept to clinical diagnosis | Neuro-Oncology | 1999 | 456 |
| 31 | Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data | Neuro-Oncology | 2018 | 443 |
| 32 | Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis | Neuro-Oncology | 2004 | 439 |
| 33 | Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study | Neuro-Oncology | 2016 | 432 |
| 34 | Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011 | Neuro-Oncology | 2015 | 414 |
| 35 | Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma | Neuro-Oncology | 2010 | 407 |
| 36 | Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma | Neuro-Oncology | 2014 | 400 |
| 37 | The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery | Neuro-Oncology | 2000 | 393 |
| 38 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019 | Neuro-Oncology | 2022 | 385 |
| 39 | Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) | Neuro-Oncology | 2017 | 381 |
| 40 | IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection | Neuro-Oncology | 2014 | 370 |
| 41 | Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 | Neuro-Oncology | 2018 | 364 |
| 42 | Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas | Neuro-Oncology | 2008 | 362 |
| 43 | Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype | Neuro-Oncology | 2007 | 354 |
| 44 | Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study | Neuro-Oncology | 2011 | 353 |
| 45 | Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention | Neuro-Oncology | 2012 | 347 |
| 46 | Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials | Neuro-Oncology | 2015 | 346 |
| 47 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study | Neuro-Oncology | 2015 | 335 |
| 48 | A multigene predictor of outcome in glioblastoma | Neuro-Oncology | 2010 | 334 |
| 49 | Limitations of stereotactic biopsy in the initial management of gliomas | Neuro-Oncology | 2001 | 329 |
| 50 | Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy | Neuro-Oncology | 2017 | 325 |
